Adenosine A2A Receptor (Adenosine A2A Receptors)

Subscribe to Selected New Research on Adenosine A2A Receptor

246 relevant articles (15 outcomes, 39 trials/studies) found for this Bio-Agent

Description: A subclass of adenosine A2 receptors found in LEUKOCYTES, the SPLEEN, the THYMUS and a variety of other tissues. It is generally considered to be a receptor for ADENOSINE that couples to the GS, STIMULATORY G-PROTEIN.

Also Known As:

Adenosine A2A Receptors; Receptor, Adenosine A2A; Adenosine A(2A) Receptor; A2A Receptor, Adenosine; A2A Receptors, Adenosine; Receptors, Adenosine A2A

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56522

Membrane Proteins: 4214

Cell Surface Receptors: 633

G-Protein-Coupled Receptors: 403

Purinergic Receptors: 214

Purinergic P1 Receptors: 1082

Adenosine A2 Receptors: 45

Adenosine A2A Receptor: 246

Neurotransmitter Receptors: 266

Purinergic Receptors: 214

Purinergic P1 Receptors: 1082

Adenosine A2 Receptors: 45

Adenosine A2A Receptor: 246

Purinergic Receptors: 214

Purinergic P1 Receptors: 1082

Adenosine A2 Receptors: 45

Adenosine A2A Receptor: 246

Experts

1.	Chen, Jiang-Fan: 10 articles (02/2008 - 11/2003)
2.	Linden, Joel: 10 articles (01/2008 - 11/2002)
3.	Popoli, Patrizia: 5 articles (01/2008 - 03/2002)
4.	Kron, Irving L: 5 articles (01/2008 - 11/2002)
5.	Morelli, Micaela: 5 articles (08/2007 - 09/2004)
6.	Ellman, Peter I: 4 articles (01/2008 - 12/2004)
7.	Schwarzschild, Michael A: 4 articles (12/2006 - 12/2003)
8.	Tribble, Curtis G: 4 articles (05/2005 - 11/2002)
9.	Kern, John A: 4 articles (05/2005 - 11/2002)
10.	Cronstein, Bruce N: 3 articles (10/2008 - 06/2004)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 11/01/2006 - "The adenosine A2A receptor has emerged as an attractive non-dopaminergic target in the pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS distribution" 03/01/2005 - "In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A(2A) receptor has emerged as an attractive nondopaminergic target" 01/01/2002 - "Since adenosine A2A receptor is selectively localized in striatum for controlling motor activity, it appeared to be an attractive target for a novel treatment in Parkinson's disease" 07/01/2005 - "Adenosine A2A receptor antagonists are orally effective in a variety of rodent models of Parkinson's disease" 03/01/2007 - "Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease" Get all the results and reference details, order at left...
2.	Wounds and Injuries (Trauma) 04/25/2008 - "Recently, activation of the adenosine A2A receptors has been shown to exert protection against peripheral tissue injuries but aggravation in the central nervous system (CNS) injuries" 04/01/2008 - "This may provide a new and efficient strategy to study the effect of adenosine A2A receptors in disease and injuries of central nervous system." 02/01/2002 - "Animal studies of the topical application of adenosine A2A receptor agonists show that it promotes wound closure" 01/01/2006 - "The effects of adenosine A2A receptors on the cells and tissues of healing wounds have only recently been explored" 06/01/2004 - "Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis." Get all the results and reference details, order at left...
3.	Ischemia 06/01/2003 - "Rapid modification of the glycocalyx caused by ischemia-reperfusion is inhibited by adenosine A2A receptor activation." 01/10/2003 - "Adenosine A(2A) receptor antagonists have been proved protective in different ischemia models" 07/01/2002 - "More recent data have shown that antagonists of adenosine A2A receptors markedly reduce cerebral ischemic damage in animal models of focal and global ischemia" 12/20/1995 - "The results indicate that the acute treatment with adenosine A2A receptor antagonists may have a limited value in treatment of global ischemia" 01/01/2008 - "CONCLUSIONS: Adenosine A2A receptor activation with ATL-313 results in the greatest protection against lung ischemia-reperfusion injury when given before ischemia and during reperfusion" Get all the results and reference details, order at left...
4.	Ulcer 01/28/2006 - "Gastric mucosal PGE2 concentration was not affected by intraperitoneal injection of ATL-146e.CONCLUSION: The specific adenosine A(2A) receptor agonist, ATL-146e, has potent anti-ulcer effects presumably mediated by its anti-inflammatory properties." 01/01/2006 - "Recent studies have demonstrated that application of topical adenosine A2A receptor agonists promotes more rapid wound closure and clinical studies are currently underway to determine the utility of topical A2A adenosine receptor agonists in the therapy of diabetic foot ulcers" 01/16/2004 - "Recent studies have demonstrated that application of topical adenosine A2A receptor agonists promotes more rapid wound closure and clinical studies are currently underway to determine the utility of topical A2A adenosine receptor agonists in the therapy of diabetic foot ulcers" 02/01/2002 - "To further confirm the efficacy of adenosine A2A receptor agonists as promoters of wound healing, we compared the effect of MRE0094, a novel selective adenosine A2A receptor agonist, to CGS-21680, a reference selective adenosine A2A receptor agonist, as well as to recombinant human platelet-derived growth factor (0.01% Becaplermin gel), an agent currently used to promote healing of diabetic ulcers, on wound closure in healthy BALB/C mice" Get all the results and reference details, order at left...
5.	Dyskinesias (Dyskinesia) 12/27/2006 - "Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice." 05/12/1999 - "CONCLUSION: Adenosine A2A receptor antagonists have antiparkinsonian effects of their own with a reduced propensity to elicit dyskinesias" 05/01/2004 - "Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias." 12/09/2003 - "Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease." 07/30/2007 - "Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, alpha2 adrenergic, serotonergic (5HT1A, 5HT2A), opioid, histamine H3, adenosine A2A receptors, the monoamine transport or cannabinoid CB1 receptors systems" Get all the results and reference details, order at left...
93 Diseases and 246 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	istradefylline
2.	Levodopa (L Dopa)
3.	Adenosine
4.	SCH 58261
5.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
6.	Adenosine A1 Receptor
7.	Glutamic Acid (Glutamate)
8.	Pentylenetetrazole (Metrazol)
9.	D-Aspartic Acid (D Aspartate)
10.	Platelet-Derived Growth Factor
148 Drugs and Important Bio-Agents and 153 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Therapeutics
2.	Debridement
3.	Activities of Daily Living (ADL)
4.	Drug Therapy (Chemotherapy)
5.	Lung Transplantation
8 Therapies and Procedures and 10 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>